A Danish drugmaker has revealed a stunning increase in pollution amid plans to boost production of its popular weight loss ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Hims & Hers Health ( HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...